Climb Bio

Recent news

• Rating change
  Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18
  Market Newswire · 2026/8/7
• Rating change
  Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG)
  TipRanks · 2026/6/15
• Rating change
  Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/8/13
• H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $24
  Market Newswire · 2026/8/24
• Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating
  Market Newswire · 2026/9/4
• Rating change
  RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
  Market Newswire · 2026/8/8
• Rating change
  A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40
  Market Newswire · 2026/9/4
• B. Riley Securities Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30
  Market Newswire · 2026/9/4
• Rating change
  Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating
  Market Newswire · 2026/6/25
• Rating change
  Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI) and Climb Bio (CLYM)
  TipRanks · 2026/7/14
• Rating change
  Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25
  Market Newswire · 2026/8/7
• Rating change
  Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $20
  Market Newswire · 2026/8/19
• Rating change
  RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23
  Market Newswire · 2026/8/3
• Rating change
  BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/8/7
• Rating change
  Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
  Market Newswire · 2026/7/30
• H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30
  Market Newswire · 2026/9/8
• Rating change
  Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $17
  Market Newswire · 2026/6/12
• Rating change
  H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/6/24
• BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32
  Market Newswire · 2026/10/2
• Rating change
  William Blair Maintains Climb Bio(CLYM.US) With Buy Rating
  Market Newswire · 2026/8/19

Headlines are aggregated automatically and are not independently verified or edited by our team.